Dr. Danong Chen is a seasoned executive with over two decades of experience in corporate strategy, product development and commercialization. She is the CEO of MetronomX Therapeutics, LLC, a company she co-founded in 2010 focusing on developing and commercializing therapeutics that addressing severely unmet medical needs such as cancer. In addition, she is a member of the Technology Council of Belle Capital.

Dr. Chen was President and Chief Executive Officer of Tanox, Inc., a Houston based, publicly traded bio-therapeutic company, which was one of the largest biotech companies in Texas. During her tenure as the CEO and President, Tanox was acquired by Genentech in 2007 in a transaction valued at about $1 billion. Prior to being named President and CEO, she served as Vice President of Strategy and Corporate Development at Tanox, responsible for guiding company strategy, evaluating new product opportunities and potential merger and acquisition transactions, and overseeing annual product prioritization and related budgeting process. From April 2008 to Aug 2009, Dr. Chen served as President and Chief Executive Officer of Theranostics Health, Inc., a biotech company focused on developing products and services for personalized medical treatments. Prior to joining Tanox, Dr. Chen served as a manager in the health-care practice of Arthur D. Little, Inc., the world's first strategic consulting company with a reputation and emphasis on innovation and technology based/guided strategies. Early in her career, she developed immunoassay-based clinical diagnostics in Shanghai, China and won a bronze medal from the Chinese government for one of the products she developed.

Dr. Chen received her Ph.D. in Neuroscience from Baylor College of Medicine in Houston, TX and MBA from Arthur D. Little School of Management in Boston, MA.